FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Oncologist - United States
doi 10.1634/theoncologist.2007-0218
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Cytotoxic Lymphocytes in B-Cell Chronic Lymphocytic Leukemia

Annals of Hematology
MedicineHematology
1990English

A Possible Risk Gene for B-Cell Chronic Lymphocytic Leukemia: NRIP1

Med One
2017English

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2012English

Lack of Allelic Exclusion in B Cell Chronic Lymphocytic Leukemia

Journal of Experimental Medicine
MedicineAllergyImmunology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy